DE69916005D1 - Effizientes Verfahren zum Auffinden von Genfunktionen mittels Bibliotheken zur funktionellen Genomanwendung - Google Patents

Effizientes Verfahren zum Auffinden von Genfunktionen mittels Bibliotheken zur funktionellen Genomanwendung

Info

Publication number
DE69916005D1
DE69916005D1 DE69916005T DE69916005T DE69916005D1 DE 69916005 D1 DE69916005 D1 DE 69916005D1 DE 69916005 T DE69916005 T DE 69916005T DE 69916005 T DE69916005 T DE 69916005T DE 69916005 D1 DE69916005 D1 DE 69916005D1
Authority
DE
Germany
Prior art keywords
libraries
efficient method
nucleic acids
gene functions
sample nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69916005T
Other languages
English (en)
Other versions
DE69916005T2 (de
Inventor
Govert Schouten
Ronald Vogels
Abraham Bout
Es Helmuth Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos Genomics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Genomics NV filed Critical Galapagos Genomics NV
Publication of DE69916005D1 publication Critical patent/DE69916005D1/de
Application granted granted Critical
Publication of DE69916005T2 publication Critical patent/DE69916005T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
DE69916005T 1998-06-12 1999-06-11 Effizientes Verfahren zum Auffinden von Genfunktionen mittels Bibliotheken zur funktionellen Genomanwendung Expired - Lifetime DE69916005T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/097,239 US6413776B1 (en) 1998-06-12 1998-06-12 High throughput screening of gene function using adenoviral libraries for functional genomics applications
US97239 1998-06-12

Publications (2)

Publication Number Publication Date
DE69916005D1 true DE69916005D1 (de) 2004-05-06
DE69916005T2 DE69916005T2 (de) 2004-09-09

Family

ID=22262382

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69916005T Expired - Lifetime DE69916005T2 (de) 1998-06-12 1999-06-11 Effizientes Verfahren zum Auffinden von Genfunktionen mittels Bibliotheken zur funktionellen Genomanwendung

Country Status (10)

Country Link
US (3) US6413776B1 (de)
EP (1) EP1022335B1 (de)
JP (1) JP3672494B2 (de)
AT (1) ATE263237T1 (de)
AU (1) AU756605B2 (de)
CA (1) CA2301403C (de)
DE (1) DE69916005T2 (de)
MX (1) MXPA00012401A (de)
NZ (1) NZ508995A (de)
WO (1) WO1999064582A2 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766891A (en) * 1994-12-19 1998-06-16 Sloan-Kettering Institute For Cancer Research Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase
DK0833934T4 (da) * 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US7883872B2 (en) 1996-10-10 2011-02-08 Dyadic International (Usa), Inc. Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose
CA2307016A1 (en) * 1997-10-24 1999-05-06 Life Technologies, Inc. Recombinational cloning using nucleic acids having recombination sites
AU3548799A (en) * 1998-04-03 1999-10-25 Invitrogen Corporation Libraries of expressible gene sequences
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
CN1230546C (zh) 1998-10-06 2005-12-07 马克·阿龙·埃马尔法尔布 丝状真菌宿主领域的转化系统
JP2002535003A (ja) * 1999-01-29 2002-10-22 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ アポトーシスを誘導するｄｎａ配列の単離方法及び検出システム
US6642052B2 (en) * 1999-02-25 2003-11-04 National Research Council Of Canada Efficient generation of adenovirus-based libraries by positive selection of adenoviral recombinants through ectopic expression of the adenovirus protease
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
EP1248856A2 (de) * 1999-12-23 2002-10-16 Xantos Biomedicine AG Screening-verfahren für nukleinsäuren
JP2003521934A (ja) 2000-02-09 2003-07-22 ジェンベク、インコーポレイティッド ウイルスベクターライブラリーの製造および使用方法
JP2003524422A (ja) 2000-02-25 2003-08-19 インヴィトロジェン コーポレーション トポイソメラーゼリンカー介在型増幅法
US7216113B1 (en) * 2000-03-24 2007-05-08 Symyx Technologies, Inc. Remote Execution of Materials Library Designs
KR20020026456A (ko) 2000-04-13 2002-04-10 에말파브 마크 아론 사상균에서 발현된 ｄｎａ 라이브러리의 고산출량 스크리닝
EP1276888A2 (de) * 2000-04-26 2003-01-22 Crucell Holland B.V. Adenovirale vektoren ohne knob-domäne im fiber protein, und verwendungen davon
ATE315086T1 (de) * 2000-08-21 2006-02-15 Invitrogen Corp Methoden und reagenzien für molekulares klonieren
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US20090118139A1 (en) * 2000-11-07 2009-05-07 Caliper Life Sciences, Inc. Microfluidic method and system for enzyme inhibition activity screening
JP2004520047A (ja) * 2000-12-08 2004-07-08 インヴィトロジェン コーポレーション 組換え型核酸分子を迅速に作製するための組成物と方法
US20060008817A1 (en) * 2000-12-08 2006-01-12 Invitrogen Corporation Methods and compositions for generating recombinant nucleic acid molecules
EP1227157A1 (de) * 2001-01-19 2002-07-31 Galapagos Genomics B.V. Swap/Gegenselektion: eine schnelles Klonierungsverfahren
IL157087A0 (en) * 2001-01-25 2004-02-08 Virxsys Corp A method for identifying a function of a gene sequence
AU2002253104A1 (en) * 2001-03-07 2002-09-19 Galapagos Genomics B.V. Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds
US20040132008A1 (en) * 2002-04-30 2004-07-08 Doranz Benjamin J Elucidation of gene function
EP1256803A1 (de) 2001-05-07 2002-11-13 Crucell Holland B.V. Verfahren zur Identifizierung von antiviralen Verbindungen
EP1409982A4 (de) * 2001-06-14 2006-05-24 Anadys Pharmaceuticals Inc Verfahren zum screening auf liganden von zielmolekülen
EP1273667A1 (de) * 2001-07-04 2003-01-08 Galapagos Genomics N.V. Hochdurchsatzidentifizierung von Angiogenese Modulatoren
ES2609014T3 (es) 2001-07-12 2017-04-18 University Of Massachusetts Producción in vivo de ARN de interferencia pequeños que median el silenciamiento génico
WO2003014346A2 (de) * 2001-08-10 2003-02-20 Xantos Biomedicine Ag Hochdurchsatz dna-isolierung und -transfektion zur analyse der funktion von genen bzw. genprodukten
WO2003018799A2 (en) * 2001-08-22 2003-03-06 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
US7647184B2 (en) 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
US20030198627A1 (en) * 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
AU2002363076A1 (en) * 2001-10-26 2003-05-06 Virtual Arrays, Inc. Assay systems with adjustable fluid communication
US7381375B2 (en) 2001-10-26 2008-06-03 Millipore Corporation Assay systems with adjustable fluid communication
US20080187949A1 (en) * 2001-10-26 2008-08-07 Millipore Corporation Multiplexed assays of cell migration
WO2003062458A2 (en) * 2002-01-24 2003-07-31 Ecopia Biosciences Inc. Method, system and knowledge repository for identifying a secondary metabolite from a microorganism
CN100335630C (zh) * 2002-06-07 2007-09-05 索菲昂生物科学有限公司 筛选方法
WO2004009768A2 (en) * 2002-07-18 2004-01-29 Invitrogen Corporation Viral vectors containing recombination sites
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CA2965865C (en) 2002-07-18 2021-10-19 Merus N.V. Recombinant production of mixtures of antibodies
CA2498319A1 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
JP4287633B2 (ja) * 2002-09-18 2009-07-01 独立行政法人科学技術振興機構 オルガネラ局在タンパク質の解析方法と解析材料
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080207465A1 (en) * 2002-10-28 2008-08-28 Millipore Corporation Assay systems with adjustable fluid communication
AU2003284609A1 (en) * 2002-11-21 2004-06-15 Genomidea Inc. Method of isolating nucleic acid having desired functional property and kit therefor
EP1573012B1 (de) 2002-12-17 2011-11-30 Crucell Holland B.V. Rekombinanter virus-basierter malaria impfstoff
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395017A3 (de) 2003-05-30 2012-12-19 Merus B.V. Entwurf und Verwendung von gepaarten unterschiedlichen Regionen von spezifisch bindenden Molekülen
WO2005001133A2 (en) * 2003-06-03 2005-01-06 Collateral Therapeutics, Inc. Compositions and methods for high throughput construction and functional analysis of expression libraries
US20050059083A1 (en) * 2003-09-15 2005-03-17 Becton Dickinson And Company High throughput method to identify ligands for cell attachment
US20050060100A1 (en) * 2003-09-15 2005-03-17 Becton Dickinson And Company Computer software and algorithms for systems biologically linked to cellular phenotype
EP2287341B1 (de) 2003-12-01 2013-02-13 Life Technologies Corporation Rekombinationsstellen enthaltende Nukleinsäuremoleküle und Verfahren zur Verwendung davon
AU2003300239A1 (en) * 2003-12-29 2005-07-21 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
NZ548828A (en) 2004-01-20 2009-07-31 Merus B V Mixtures of binding proteins
AU2005250325A1 (en) * 2004-04-15 2005-12-15 Allied Biotech, Inc. Methods and apparatus for detection of viral infection
EP2267458A3 (de) 2004-04-20 2011-04-06 Galapagos N.V. Verfahren, Zusammensetzungen und Verbindungstests zur Hemmung der Amyloid-beta-proteinproduktion
GB0410105D0 (en) * 2004-05-06 2004-06-09 Amersham Biosciences Uk Ltd Method for characterising compounds
EP1773997B1 (de) 2004-06-14 2011-11-23 Galapagos N.V. Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen
WO2005124342A2 (en) 2004-06-21 2005-12-29 Galapagos N.V. Methods and means for treatment of osteoarthritis
US7485468B2 (en) 2004-10-15 2009-02-03 Galapagos Bv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
ES2679282T3 (es) 2004-10-22 2018-08-23 Revivicor Inc. Porcinos transgénicos que carecen de cadena ligera de inmunoglobulina endógena
WO2008073914A2 (en) 2006-12-10 2008-06-19 Dyadic International Inc. Expression and high-throughput screening of complex expressed dna libraries in filamentous fungi
EP2162747B1 (de) 2007-06-20 2014-04-30 Galapagos N.V. Molekulaire targets und verfahren zur identifikation von substanzen für die behandlung von degenerativen knochen- und gelenkserkrankungen
EP2197893B1 (de) 2007-09-07 2013-07-24 Dyadic International, Inc. Neue pilzenzyme
CL2009001064A1 (es) 2008-05-07 2009-10-09 Galapagos Nv Compuestos derivados de imidazol-pirazina o triazol-pirazina fusionados, inhibidores de mapkapk5; composicion farmaceutica que comprende dichos compuestos; y uso para preparar un medicamento destinado al tratamiento de inflamacion, especialmente en la artritis reumatoide.
CA2736425A1 (en) 2008-09-11 2010-03-18 Galapagos Nv Method for identifying compounds useful for increasing the functional activity and cell surface expression of cf-associated mutant cystic fibrosis transmembrane conductance regulator
EP2348827B1 (de) 2008-10-27 2015-07-01 Revivicor, Inc. Immunsupprimierte huftiere
WO2011015572A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
WO2011015573A1 (en) 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
TW201120043A (en) 2009-11-05 2011-06-16 Galapagos Nv Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
SG11201402633UA (en) 2011-11-28 2014-09-26 Crucell Holland Bv Influenza virus vaccines and uses thereof
KR102171431B1 (ko) 2012-04-20 2020-10-30 메뤼스 엔.페. Ig-유사 분자의 제조방법 및 제조수단
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
US20170247762A1 (en) 2014-10-27 2017-08-31 The Board Institute Inc. Compositions, methods and use of synthetic lethal screening
EP3757211A1 (de) 2014-12-19 2020-12-30 The Broad Institute, Inc. Verfahren zur profilierung des t-zell-rezeptor-repertoirs
EP3234193B1 (de) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molekulare biomarker für krebsimmuntherapie
AU2016264623B2 (en) 2015-05-20 2022-06-30 Dana-Farber Cancer Institute, Inc. Shared neoantigens
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
EP3336169A1 (de) * 2016-12-15 2018-06-20 Institut Polytechnique de Grenoble Robotisches verfahren zum beschichten einer multiwellplatte durch einen mehrschichtigen polyelektrolytfilm
EP3574116A1 (de) 2017-01-24 2019-12-04 The Broad Institute, Inc. Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
BR112019016657A2 (pt) 2017-02-12 2020-04-07 Neon Therapeutics Inc métodos baseados em hla e composições e usos destes
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
US20210163926A1 (en) * 2018-01-04 2021-06-03 Arizona Board Of Regents On Behalf Of Arizona State University Versatile amplicon single-cell droplet sequencing-based shotgun screening platform to accelerate functional genomics
WO2020072700A1 (en) 2018-10-02 2020-04-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
EP4003430A1 (de) 2019-07-23 2022-06-01 Janssen Biotech, Inc. Synthetische genetische elemente zur bioherstellung
CN116249774A (zh) 2020-05-26 2023-06-09 迪奥尼斯治疗公司 核酸人工微型蛋白质组文库
JP2024501482A (ja) 2020-12-14 2024-01-12 ビオンテック ユーエス インコーポレイテッド がん免疫療法のための組織特異的抗原
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
US4727028A (en) 1981-06-22 1988-02-23 Eli Lilly And Company Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US5208149A (en) 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4740463A (en) 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
US5518913A (en) 1991-10-10 1996-05-21 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
CA2053187A1 (en) 1991-10-10 1993-04-11 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
US6057427A (en) 1991-11-20 2000-05-02 Trustees Of Dartmouth College Antibody to cytokine response gene 2(CR2) polypeptide
FR2698880B1 (fr) 1992-11-25 1995-02-24 Inst Nat Sante Rech Med Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques.
AU680459B2 (en) 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2707664B1 (fr) 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
EP0667912B1 (de) 1993-07-13 2008-07-02 Centelion Defekte adenovirus-vektoren und deren verwendung in der gentherapie
US5401744A (en) 1993-10-04 1995-03-28 Bristol-Myers Squibb Company Useful hemi-hydrate form of a cerebral function enhancing agent
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
EP1548118A2 (de) 1994-06-10 2005-06-29 Genvec, Inc. Komplementäre adenovirale Vektor-Systeme und Zelllinien
CA2156132A1 (en) 1994-08-16 1996-02-17 Abraham Bout Recombinant vectors derived from adenovirus for use in gene therapy
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
CA2239366A1 (en) * 1996-01-05 1997-07-17 Genetic Therapy, Inc. Recombinase-mediated generation of adenoviral vectors
DE69722176T2 (de) 1996-01-23 2004-03-18 The Board Of Trustees Of The Leland Stanford Junior University, Palo Alto Verfahren zur suche nach transdominanten effektorpeptiden und rna-molekülen
US6197502B1 (en) 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
CA2315242C (en) * 1997-12-19 2005-02-08 Genetrace Systems, Inc. Non-bacterial cloning in delivery and expression of nucleic acids
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy

Also Published As

Publication number Publication date
NZ508995A (en) 2003-12-19
US6413776B1 (en) 2002-07-02
JP2002526031A (ja) 2002-08-20
AU4294799A (en) 1999-12-30
EP1022335B1 (de) 2004-03-31
US7029848B2 (en) 2006-04-18
JP3672494B2 (ja) 2005-07-20
CA2301403A1 (en) 1999-12-16
MXPA00012401A (es) 2003-07-14
WO1999064582A3 (en) 2000-04-06
US6340595B1 (en) 2002-01-22
US20030027170A1 (en) 2003-02-06
AU756605B2 (en) 2003-01-16
CA2301403C (en) 2009-01-06
DE69916005T2 (de) 2004-09-09
WO1999064582A2 (en) 1999-12-16
ATE263237T1 (de) 2004-04-15
EP1022335A1 (de) 2000-07-26

Similar Documents

Publication Publication Date Title
ATE263237T1 (de) Effizientes verfahren zum auffinden von genfunktionen mittels bibliotheken zur funktionellen genomanwendung
DE60039037D1 (de) Methode zur direkten sequenzierung von nukleinsäuren
WO2004083225A3 (fr) Biopuces a sondes et leurs methodes d’utilisation
ATE118818T1 (de) Verfahren zur herstellung synthetischer oligonukleotide, die spezifisch an bestimmungsstellen auf duplex-dna-molekülen binden durch formen eines kolinearen triplex, die synthetischen oligonukleotide und verfahren zu ihrer herstellung.
ATE118549T1 (de) Verfahren zur synthese von ribonukleinsäure (rns).
ATE343586T1 (de) Verfahren zur verwendung einer universellen bibliothek von peptid-nukleinsäuren zur optimierung der dns-hybridisierung
ATE141956T1 (de) Verfahren zur vervielfältigung von nukleinsäuresequenzen
DE60127162D1 (de) Massives Parallelverfahren zur Dekodierung von DNA und RNA
ATE545710T1 (de) Verfahren zur vervielfältigung von nukleinsäuren
ATE377074T1 (de) Methode zur bereitstellung von dna sequenzen
AU2003291610A1 (en) Method to generate or determine nucleic acid tags corresponding to the terminal ends of dna molecules using sequences analysis of gene expression (terminal sage)
WO2000022171A3 (en) Systems and methods for sequencing by hybridization
DE50008148D1 (de) Verfahren zur charakterisierung von nukleinsäurefragmenten
ATE211180T1 (de) Verfahren zur nicht-radioaktiven detektion von membran-gebundenen nukleinsäuren und testkit
ATE264865T1 (de) Verfahren zum nachweis von biologischen materialen mit boviner herkunft, und oligonukleotiden die es gebraucht
ATE396281T1 (de) Quantifizierungsverfahren für genetische modifikationen unter verwendung von standardmolekülen
DE59410068D1 (de) Verfahren zur spezifischen Klonierung von Nukleinsäuren
ATE144557T1 (de) Nucleinsäure-proben und verfahren zum nachweis von giardia lamblia
DE50014875D1 (de) Verfahren zum herstellen eines rekombinanten proteins
ATE317123T1 (de) Reaktiver träger zur bestimmung von dna fragmenten
PT778347E (pt) Proteina ligante a atp e acidos nucleicos com propriedade de helicase e de atpase
WO2000021984A3 (en) Nucleic acids encoding human cide-b protein and polymorphic markers thereof
WO2001040510A3 (de) Dynamische sequenzierung durch hybridisierung
EP1182212A3 (de) Ultraspiracle (USP)-Protein von Heliothis virescens
WO2000075362A3 (en) Method for identifying novel transcriptional regulatory proteins

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: GALAPAGOS N.V., MECHELEN, BE